<DOC>
	<DOCNO>NCT00573131</DOCNO>
	<brief_summary>OncoGel new experimental drug delivery system allow slow continuous release paclitaxel ( approve intravenous anticancer drug ) , gel ( ReGel ) long period time . The gel disappear 4 6 week release paclitaxel . The protocol direct towards evaluate efficacy safety paclitaxel deliver local , intralesional treatment use combination chemotherapy ( cisplatin 5-FU ) radiation therapy surgery .</brief_summary>
	<brief_title>Efficacy Safety OncoGel™ Added Chemotherapy Radiation Before Surgery Subjects With Esophageal Cancer</brief_title>
	<detailed_description>The primary objective study evaluate efficacy OncoGel give combination standard chemotherapy ( cisplatin 5-FU ) radiation therapy patient previously untreated , resectable , local local-regional adenosarcoma squamous cell carcinoma . All patient receive IV cisplatin Day 1 Day 29 IV 5-FU give continuously 96 hour start Day 1 Day 29 . All patient also receive out-patient radiation therapy 28 treatment per day 5 1/2 week start Day 1 . Patients randomized OncoGel treatment group OncoGel dose inject esophageal tumor endoscopic procedure start systemic chemotherapy radiation therapy . All patient CT scan tumor measurement start chemotherapy 12 week later completion radiation therapy cycle chemotherapy . During chemotherapy radiation therapy , physical exam , vital sign , routine blood test perform . Patients also ask quality life ability swallow . In-patient surgery schedule 4 6 week completion chemotherapy radiation therapy . The resected esophagus lymph node evaluate presence residual tumor . Patients follow month 4 , 5 , 6 , every 3 Months thereafter survival esophageal cancer status treatment last patient enrol complete Month 12 visit .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Histologically cytologically confirm squamous cell carcinoma adenocarcinoma esophagus . Stage T2T3 , N , M0 ( evidence disseminate cancer except regional involvement may designate `` M1a '' ) . No evidence metastatic disease 2 . Medically able tolerate major abdominal and/or thoracic surgery 3 . Able undergo EUS procedure pas EUS probe esophageal lumen 4 . Able receive concurrent systemic chemotherapy ( cisplatin 5FU ) RT 5 . Clinical management plan include esophagectomy completion two course chemoradiation therapy 6 . Karnofsky Performance Status ≥ 60 7 . Minimum life expectancy 4 month 8 . Hematologic function Absolute neutrophil count ( ANC ) ≥ 1500/mm3 Platelet count ≥ 100,000/mm3 Hemoglobin ≥ 9 g/dL 9 . Hepatic function : Total bilirubin &lt; 1.5 X upper limit normal ( ULN ) AST ALT &lt; 3 X ULN Albumin ≥ 3.0 g/dL ≥ 2.0 g/dL low level consider investigator due nutritional depletion 10 . Serum creatinine &lt; 1.5 mg/dL and/or creatinine clearance ≥ 65 mL/min 11 . ≥ 18 year old 12 . If female , must nonpregnant , nonlactating , nonchildbearing potential , use adequate birth control 13 . Capable understand agree fulfill requirement protocol 14 . Sign IRB/EC approve consent form 1 . History anaphylaxis plan CT contrast agent 2 . Prior esophageal stent insertion , laser , photodynamic therapy 3 . Prior chest RT major esophageal surgery 4 . Any prior receipt cytotoxic chemotherapeutic agent 5 . Prior receipt cancer treatment ( ie , Chelation therapy ) , vaccine , biological response modifiers/growth factor ( ie , GMCSF , IL2 ) within past 4 week . 6 . Prior malignancy unless disease free ≥ 3 year . Note : basal cell/squamous carcinoma skin , situ cervical breast carcinoma , superficial transitional cell bladder carcinoma allow . Subjects history low risk prostatic carcinoma ( ie , clinical stage 1 2a , Gleason score &lt; = 6 PSA &lt; 10 ng/mL diagnosis ) allow 7 . Significant currently active systemic disease include uncontrolled diabetes , severe heart disease ( New York Heart Association Class III IV ) , uncontrolled hypertension , myocardial infarction within 3 month , severe bronchial obstruction , uncontrolled seizure disorder , peripheral neuropathy great CTCAE grade 1 8 . Allergies active inactive component OncoGel ( ie , allergy degradable PLGA [ poly ( lactidecoglycolide ) suture ] ) 9 . Receipt investigational drug device within 30 day prior sign inform consent 10 . Any medical condition circumstance , Investigator 's opinion , would prevent completion study , interfere analysis study result , potentially adversely affect subject safety 11 . Known esophageal varix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Esophageal cancer</keyword>
	<keyword>Localized esophageal cancer</keyword>
	<keyword>Operable esophageal cancer</keyword>
	<keyword>Loco-regional esophageal cancer</keyword>
	<keyword>Esophagectomy</keyword>
	<keyword>Phase 2</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Tumor</keyword>
	<keyword>Local</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>radiation therapy</keyword>
	<keyword>surgery</keyword>
	<keyword>OncoGel</keyword>
	<keyword>Squamous cell carcinoma esophagus</keyword>
</DOC>